Open Access T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody
Author(s) -
Mounia S. Braza,
Bernard Klein,
Geneviève Fiol,
JeanFrançois Rossi
Publication year - 2010
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2010.029520
Subject(s) - monoclonal antibody , cytotoxic t cell , cytotoxicity , cd20 , perforin , follicular lymphoma , antibody , antibody dependent cell mediated cytotoxicity , granzyme b , granzyme , microbiology and biotechnology , biology , cancer research , chemistry , immunology , lymphoma , in vitro , biochemistry
Anti-CD20 monoclonal antibodies are major therapeutic agents for patients with follicular lymphoma and work through complement-mediated cytotoxicity and antibody-dependent cellular cytotoxicity. Optimization of antibody-dependent cellular cytotoxicity, in particular by amplifying its effectors, could further increase the efficacy of anti-CD20 monoclonal antibodies.